{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:05:33Z","timestamp":1790791533881,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Modern molecular diagnostic techniques such as DNA methylation profiling are leading to the reclassification of several central nervous system malignancies and discovery of novel diagnostic entities, such as high-grade glioma with pleomorphic and pseudopapillary features (HPAP).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We performed a retrospective chart review of all patients with HPAP confirmed with methylation profiling at a single institution between 2023 and 2025. Demographic, radiographic, surgical, and outcome data were collected.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Three patients were identified: two females and one male with a mean age of 49.7 years (range 25\u201362). No patients had a prior cancer history. One patient had an incidentally discovered tumor, while the other two patients underwent imaging for symptoms of headache, vision changes and extremity weakness. Mean tumor size was 4.0\u00a0cm (range 2.8-6) with a wide variation in imaging characteristics. All patients underwent surgical resection and radiographic gross total resection was achieved in all cases. All patients underwent radiation therapy without concurrent chemotherapy. After a median 20 months follow up (range 4.5 to 108.9), two patients experienced tumor progression at 2.7 months and 86.5 months respectively. All patients were alive at last follow up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>HPAP is a novel clinical entity demonstrating variable molecular signatures sharing a common DNA methylation profile which demonstrates a relatively favorable clinical course when compared with other high grade gliomas. Further study is needed to determine the optimal treatment and factors that influence survival.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40478-025-02097-7","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T11:38:02Z","timestamp":1755517082000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["High-grade glioma with pleomorphic and pseudopapillary features: a single-institution series of three cases"],"prefix":"10.1186","volume":"13","author":[{"given":"Eric A.","family":"Goethe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"Alfattal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhiksha","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pushan","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Puduvalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiao-Pei","family":"Weathers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leomar Y.","family":"Ballester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Weinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujit","family":"Prabhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherise D.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Gubbiotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"issue":"1","key":"2097_CR1","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40478-025-01987-0","volume":"13","author":"EA Goethe","year":"2025","unstructured":"Goethe EA, Srinivasan S, Kumar S, Prabhu SS, Gubbiotti MA, Ferguson SD (2025) High-grade Astrocytoma with piloid features: a single-institution case series and literature review. Acta Neuropathol Commun 13(1):82. https:\/\/doi.org\/10.1186\/s40478-025-01987-0","journal-title":"Acta Neuropathol Commun"},{"issue":"3","key":"2097_CR2","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00401-009-0550-z","volume":"118","author":"A Korshunov","year":"2009","unstructured":"Korshunov A, Meyer J, Capper D et al (2009) Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic Astrocytoma from diffuse Astrocytoma. Acta Neuropathol 118(3):401\u2013405. https:\/\/doi.org\/10.1007\/s00401-009-0550-z","journal-title":"Acta Neuropathol"},{"issue":"2","key":"2097_CR3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s11060-024-04741-z","volume":"169","author":"B Decraene","year":"2024","unstructured":"Decraene B, Coppens G, Spans L et al (2024) A novel methylation signature predicts extreme long-term survival in glioblastoma. J Neurooncol 169(2):341\u2013347. https:\/\/doi.org\/10.1007\/s11060-024-04741-z","journal-title":"J Neurooncol"},{"issue":"3","key":"2097_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00401-022-02404-9","volume":"143","author":"D Pratt","year":"2022","unstructured":"Pratt D, Abdullaev Z, Papanicolau-Sengos A et al (2022) High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent TP53 mutations and recurrent monosomy 13. Acta Neuropathol 143(3):403\u2013414. https:\/\/doi.org\/10.1007\/s00401-022-02404-9","journal-title":"Acta Neuropathol"},{"issue":"1","key":"2097_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s40478-025-02017-9","volume":"13","author":"S Rossi","year":"2025","unstructured":"Rossi S, Giovannoni I, Patrizi S et al (2025) Expanding clinicopathologic knowledge in high-grade glioma with pleomorphic and pseudopapillary features (HPAP): a report of two cases. Acta Neuropathol Commun 13(1):97. https:\/\/doi.org\/10.1186\/s40478-025-02017-9","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"2097_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/jnen\/nlad114","volume":"83","author":"MA Gubbiotti","year":"2024","unstructured":"Gubbiotti MA, Weinberg JS, Weathers SP et al (2024) An incidental finding of a high-grade glioma with pleomorphic and pseudopapillary features (HPAP) with PBRM1 mutation. J Neuropathol Exp Neurol 83(2):139\u2013141. https:\/\/doi.org\/10.1093\/jnen\/nlad114","journal-title":"J Neuropathol Exp Neurol"},{"issue":"8","key":"2097_CR7","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.3390\/cancers16081558","volume":"16","author":"MF Huang","year":"2024","unstructured":"Huang MF, Wang YX, Chou YT, Lee DF (2024) Therapeutic strategies for RB1-Deficient cancers: intersecting gene regulation and targeted therapy. Cancers (Basel) 16(8):1558. https:\/\/doi.org\/10.3390\/cancers16081558","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2097_CR8","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1158\/2159-8290.CD-18-0469","volume":"9","author":"X Gong","year":"2019","unstructured":"Gong X, Du J, Parsons SH et al (2019) Aurora A kinase Inhibition is synthetic lethal with loss of the RB1 tumor suppressor gene. Cancer Discov 9(2):248\u2013263. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0469","journal-title":"Cancer Discov"},{"key":"2097_CR9","doi-asserted-by":"publisher","first-page":"5105","DOI":"10.1038\/s41467-020-18872-0","volume":"11","author":"J Lyu","year":"2020","unstructured":"Lyu J, Yang EJ, Zhang B et al (2020) Synthetic lethality of RB1 and Aurora A is driven by stathmin-mediated disruption of microtubule dynamics. Nat Commun 11:5105. https:\/\/doi.org\/10.1038\/s41467-020-18872-0","journal-title":"Nat Commun"},{"issue":"3","key":"2097_CR10","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/kjm2.12469","volume":"38","author":"W Yang","year":"2022","unstructured":"Yang W, Jiang XX, Zhao XY, Mao PA (2022) Treatment of RB-deficient retinoblastoma with Aurora-A kinase inhibitor. Kaohsiung J Med Sci 38(3):244\u2013252. https:\/\/doi.org\/10.1002\/kjm2.12469","journal-title":"Kaohsiung J Med Sci"},{"key":"2097_CR11","doi-asserted-by":"publisher","unstructured":"Dong Q, Yu T, Chen B et al Mutant RB1 enhances therapeutic efficacy of PARPis in lung adenocarcinoma by triggering the cGAS\/STING pathway. JCI Insight. 8(21):e165268. https:\/\/doi.org\/10.1172\/jci.insight.165268","DOI":"10.1172\/jci.insight.165268"},{"key":"2097_CR12","doi-asserted-by":"publisher","first-page":"7064","DOI":"10.1038\/s41467-021-27291-8","volume":"12","author":"G Zoumpoulidou","year":"2021","unstructured":"Zoumpoulidou G, Alvarez-Mendoza C, Mancusi C et al (2021) Therapeutic vulnerability to PARP1,2 Inhibition in RB1-mutant osteosarcoma. Nat Commun 12:7064. https:\/\/doi.org\/10.1038\/s41467-021-27291-8","journal-title":"Nat Commun"},{"issue":"21","key":"2097_CR13","doi-asserted-by":"publisher","first-page":"5377","DOI":"10.3390\/cancers14215377","volume":"14","author":"K Szklener","year":"2022","unstructured":"Szklener K, Mazurek M, Wieteska M, Wac\u0142awska M, Bilski M, Ma\u0144dziuk S (2022) New directions in the therapy of glioblastoma. Cancers (Basel) 14(21):5377. https:\/\/doi.org\/10.3390\/cancers14215377","journal-title":"Cancers (Basel)"},{"issue":"12","key":"2097_CR14","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.3390\/cancers13122968","volume":"13","author":"A Kommalapati","year":"2021","unstructured":"Kommalapati A, Tella SH, Borad M, Javle M, Mahipal A (2021) FGFR inhibitors in oncology: insight on the management of toxicities in clinical practice. Cancers (Basel) 13(12):2968. https:\/\/doi.org\/10.3390\/cancers13122968","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2097_CR15","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1038\/s41467-022-30666-0","volume":"13","author":"RC Coombes","year":"2022","unstructured":"Coombes RC, Badman PD, Lozano-Kuehne JP et al (2022) Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer. Nat Commun 13(1):3246. https:\/\/doi.org\/10.1038\/s41467-022-30666-0","journal-title":"Nat Commun"},{"issue":"11","key":"2097_CR16","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1158\/1078-0432.CCR-21-2664","volume":"28","author":"AB Lassman","year":"2022","unstructured":"Lassman AB, Sep\u00falveda-S\u00e1nchez JM, Cloughesy TF et al (2022) Infigratinib in patients with recurrent gliomas and FGFR alterations: A multicenter phase II study. Clin Cancer Res 28(11):2270\u20132277. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2664","journal-title":"Clin Cancer Res"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-02097-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-025-02097-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-02097-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T14:08:50Z","timestamp":1755785330000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-025-02097-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2097"],"URL":"https:\/\/doi.org\/10.1186\/s40478-025-02097-7","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the University of Texas MD Anderson Cancer Center Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"176"}}